Schering to close plant
Schering-Plough will effectively close its Manati, Puerto Rico manufacturing site by the end of 2006, the company announced June 1. The company also will make staff reductions at its facilities in Las Piedras, P.R., and New Jersey. A total of about 1,100 positions will be eliminated. Costs of the closures are expected to be between $235 mil. and $260 mil. Schering anticipates the reductions will create annual cost reductions around $100 mil. beginning in 2007...
You may also be interested in...
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.
After a high-profile launch early this year, first-mover Perrigo has recalled its albuterol sulfate aerosol in the US following complaints of inhalers failing to dispense due to “clogging.” The firm has revealed the expected financial impact of the move as well as commenting on how long it expects the product to be off the market, during which albuterol rivals Cipla and Lupin could benefit.
Analysts agree that new Phase III data suggests the antibody-drug conjugate will be a new standard of care in third-line TNBC, with potential in earlier treatment lines and in several other tumor types.